In the ongoing human effort to outmaneuver cancer's defenses, a Chinese clinical trial has offered a quietly significant finding: a two-drug combination targeting the HER2 protein from both inside and outside the cell achieved complete tumor elimination in 60% of women with advanced breast cancer before surgery. The neoPICD trial, conducted across seven centers in China, enrolled 108 evaluable patients and produced response rates that rival or exceed some current global standards. While the absence of a direct comparison group tempers certainty, the results invite a deeper question about wheth
The ASCO Post
· Jul 24, 2026
· health
· 4 min de leitura
High
Apuração: Verificado
Dual HER2-Targeted Combo Achieves 60% Pathologic Response in Advanced Breast Cancer
◉
Health & Medicine
6426 artigos relacionados
Researchers uncover how bacteria survive antibiotics through tolerance…
News-Medical · 100% correspondência
Mix-and-match COVID boosters offer immune system flexibility, expert e…
The Conversation · 99% correspondência
FDA poised to approve scaled COVID vaccine for children ages 5-11
Futurity: Research News · 99% correspondência
Context matters: Why vaccinated people dominate COVID hospital numbers
The Canberra Times · 99% correspondência
Pharma M&A Surge Amid Drug Price Scrutiny, Bird Flu Vaccination Push
Devdiscourse · 99% correspondência
Cobertura Relacionada
Google News · Jul 24
Current Ebola outbreak spreads faster than any recorded epidemic
The 2026 Ebola outbreak in Democratic Republic of Congo is spreading faster than any previous outbreak, with death toll …
BBC News · Jul 24 Unknown rescuer saves two children as mother and daughter drown at Essex beachA brave day-tripper rescued two children during a beach incident in Essex where a mother and daughter drowned while atte…
allAfrica.com · Jul 24 Botswana Grapples With 81,000 NCD Cases Amid Drug ShortagesPresident Boko reports 81,000 Batswana living with non-communicable diseases while pledging to resolve critical drug sho…
American Council on Science and Health · Jul 24 Why 'There's a Study' Isn't Proof: ADHD Treatment Claims Need ScrutinySocial media promotes unproven ADHD treatments while medication—the most evidence-backed option—faces discontinuation. T…
Viés e Enquadramento
⚖
Medical journal article presenting clinical trial results with factual reporting, minimal bias detected, though geographic focus and drug approval status warrant consideration.
Bias Direction
center
Confidence
MED
Objective clinical reporting with emphasis on efficacy metrics and mechanistic rationale. Comparative framing positions new combination against established standard (trastuzumab/pertuzumab) using response rate ranges.
high pathologic response rates
exceeding some standard treatments
substantial proportion of patients still do not achieve
Safety/toxicity profile comparison with standard regimens
Cost-effectiveness or accessibility considerations
Patient-reported outcomes or quality of life data
Perspectives from oncologists outside China
Limitations or potential criticisms of single-arm trial design
Long-term follow-up data or recurrence rates
Impacto Geopolítico
🌎
Chinese-developed HER2-targeted cancer drugs demonstrate superior efficacy, potentially reducing Western pharmaceutical dominance in oncology and signaling China's biotech advancement.
Escalation Risk
low
Confidence
MED
China
United States
Singapore
European Union
Asia-Pacific
China's development of inetetamab and pyrotinib represents a shift in pharmaceutical innovation from Western monopoly toward multi-polar biotech competition. Success in clinical trials strengthens China's position in global oncology markets and reduces dependence on U.S./EU drugs. This challenges Western pharmaceutical pricing power and regulatory influence, while positioning China as a credible innovator rather than solely a generic manufacturer.
Similar to China's advancement in solar panel and EV battery manufacturing—moving from imitation to innovation leadership in strategic sectors, now extending to high-value pharmaceuticals.
Lente Econômica
📈
Chinese dual HER2-targeted therapy achieves 60% pathologic response in breast cancer, potentially expanding treatment options and creating market opportunities in oncology therapeutics.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Oncology/Cancer Treatment
Medical Devices & Diagnostics
Healthcare Services
Healthcare Insurance
Patients with HER2-positive breast cancer may gain access to potentially more effective treatment options with higher response rates, though availability depends on regulatory approval and pricing. Improved outcomes could reduce long-term healthcare costs for some patients.
FDA approval pathway likely for inetetamab and pyrotinib in US markets; potential for accelerated review given superior efficacy data. May influence treatment guidelines and reimbursement policies. Could accelerate Chinese pharmaceutical innovation recognition globally and impact competitive dynamics in HER2-targeted therapy market.